In Korea, HAfiller-related complications are common and ASCs are widelyused to manage this problem. Unlike hyaluronidase treatment,the use of ASCs is very effective at recovering ischemia until 4-5days after the onset of complications and can reduce the area ofnecrosis even 7 days after the onset